Collegium Pharmaceutical (NASDAQ:COLL) had its target price raised by analysts at Needham & Company LLC from $25.00 to $28.00 in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 65.29% from the company’s current price. The analysts noted that the move was a valuation call.

Other analysts also recently issued research reports about the stock. Jefferies Group lifted their target price on shares of Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a report on Tuesday. Piper Jaffray Companies set a $19.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, November 29th. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, November 17th. Finally, Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Monday, November 13th. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $22.67.

Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $16.94 on Tuesday. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $19.21.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm had revenue of $11.95 million during the quarter, compared to the consensus estimate of $5.31 million. During the same quarter last year, the firm earned ($1.13) EPS. The firm’s revenue for the quarter was up 2814.6% on a year-over-year basis. sell-side analysts forecast that Collegium Pharmaceutical will post -2.56 earnings per share for the current fiscal year.

In other Collegium Pharmaceutical news, insider Alison B. Fleming sold 4,601 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total value of $79,367.25. Following the completion of the transaction, the insider now owns 28,513 shares in the company, valued at $491,849.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the transaction, the chief executive officer now owns 558,987 shares of the company’s stock, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,630 shares of company stock valued at $924,360. Insiders own 25.76% of the company’s stock.

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Collegium Pharmaceutical by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock worth $8,113,000 after purchasing an additional 58,398 shares during the last quarter. Teton Advisors Inc. purchased a new stake in shares of Collegium Pharmaceutical during the 3rd quarter worth $283,000. Bank of New York Mellon Corp lifted its position in shares of Collegium Pharmaceutical by 60.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock worth $1,313,000 after purchasing an additional 39,656 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 98.8% during the 2nd quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock worth $745,000 after purchasing an additional 29,617 shares during the last quarter. Finally, Pier Capital LLC lifted its position in shares of Collegium Pharmaceutical by 8.1% during the 2nd quarter. Pier Capital LLC now owns 395,658 shares of the specialty pharmaceutical company’s stock worth $4,950,000 after purchasing an additional 29,594 shares during the last quarter. Institutional investors and hedge funds own 79.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Collegium Pharmaceutical (COLL) PT Raised to $28.00 at Needham & Company LLC” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/05/collegium-pharmaceutical-coll-pt-raised-to-28-00-at-needham-company-llc.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.